Last reviewed · How we verify
NCT04598087
Prehabilitation and Recovery After Head and Neck Cancer Surgery
Status unknown
NA
Last updated 7 March 2022
What this trial tests
NA trial testing Prehabilitation in Head and Neck Cancer in 96 participants. Status unknown.
Timeline
9 February 2022
Primary endpoint
31 December 2023
31 December 2023
31 December 2024
Quick facts
| Lead sponsor | University of Calgary |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 96 |
| Start date | 9 February 2022 |
| Primary completion | 31 December 2023 |
| Estimated completion | 31 December 2024 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Prehabilitation
Conditions studied
- Head and Neck Cancer — all drugs for Head and Neck Cancer →
- Head and Neck Neoplasms — all drugs for Head and Neck Neoplasms →
- Surgery — all drugs for Surgery →
Sponsor
University of Calgary
Who can join
18 and older, any sex, with Head and Neck Cancer or Head and Neck Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Implementing a multiphasic, multimodal prehabilitation intervention for people undergoing surgery with free flap reconstruction for the treatment of head and neck cancer.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
A Qualitative Study of Patient and Healthcare Provider Perspectives on Building Multiphasic Exercise Prehabilitation into the Surgical Care Pathway for Head and Neck Cancer.
Daun JT, Twomey R, Dort JC, Capozzi LC, et al · · 2022 · cited 18× · PMID 36005207 · DOI 10.3390/curroncol29080469 -
Effect of exercise across the head and neck cancer continuum: a systematic review of randomized controlled trials.
Avancini A, Borsati A, Belluomini L, Giannarelli D, et al · · 2023 · cited 17× · PMID 37924500 · DOI 10.1007/s00520-023-08126-2 -
Tailoring the Evidence for Exercise Oncology within Breast Cancer Care.
Wagoner CW, Capozzi LC, Culos-Reed SN. · · 2022 · cited 13× · PMID 35877243 · DOI 10.3390/curroncol29070383 -
Head and Neck Cancer (HNC) Prehabilitation: Advantages and Limitations.
Demurtas S, Cena H, Benazzo M, Gabanelli P, et al · · 2024 · cited 9× · PMID 39458125 · DOI 10.3390/jcm13206176 -
Multiphasic exercise prehabilitation for patients undergoing surgery for head and neck cancer: a hybrid effectiveness-implementation study protocol.
Wagoner CW, Daun JT, Danyluk J, Twomey R, et al · · 2023 · cited 9× · PMID 38012345 · DOI 10.1007/s00520-023-08164-w -
The feasibility of patient-reported outcomes, physical function, and mobilization in the care pathway for head and neck cancer surgical patients.
Daun JT, Twomey R, Capozzi LC, Crump T, et al · · 2022 · cited 7× · PMID 35624523 · DOI 10.1186/s40814-022-01074-4
Verify or expand the search:
- PubMed search for NCT04598087
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Prehabilitation
Trials testing the same drug.
- NCT07394582 — Preoperative Optimization Before Total Hip or Knee Replacement Surgery · NA · recruiting
- NCT07145957 — Does Undergoing a Prehabilitation Protocol Aimed at Optimizing Scapulothoracic Mobility and Strengthening Improve Intern · recruiting
- NCT06874413 — Targeted Prehabilitation With Physical Exercise and Inspiratory Muscle Training for Elderly Frail Patients Prior to Vent · NA · enrolling by invitation
- NCT06830967 — Virtual Prehabilitation for Patients Undergoing Abdominal Aortic Aneurysm Repair · NA · not yet recruiting
- NCT06716437 — Prehabilitation for Patients Undergoing Lung Cancer Surgery · NA · recruiting
Other recruiting trials for Head and Neck Cancer
Currently open trials in the same condition.
- NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
- NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
- NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting
Other University of Calgary trials
Trials by the same sponsor.
- NCT06885996 — Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence · Phase 2 · not yet recruiting
- NCT05729503 — Effect of SPG Block for Patients With Anxiety at Electronic Dance Music Festivals · Phase 2 · not yet recruiting
- NCT07463339 — Microbiome-guided Prophylaxis to Reduce Ventilator-Associated Pneumonia in Intensive Care Units: A Pilot Randomized Cont · Phase 2 · not yet recruiting
- NCT07145645 — Topical Diclofenac vs.Oral Ibuprofen for MSK Pain in Children · Phase 3 · recruiting
- NCT07280325 — Moxie Self-Management and Education Support Program · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04598087 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Calgary
- Last refreshed: 7 March 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04598087.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing